[ORGANIZATION]
Priovant Therapeutics
Featured in 2 tracked stories · first seen
Situations
FDA approval of Lisraya for dermatomyositis
2 clusters · 15 sources · last updated
Latest: FDA approves new treatments for dermatomyositis and polycythemia vera
The U.S. Food and Drug Administration (FDA) has approved Lisraya (brepocitinib), developed by Priovant Therapeutics, as the first targeted oral therapy specifically for adults with dermatomyositis. This rare autoimmune d